34βE12 cytokeratin immunodetection in the differential diagnosis of neuroendocrine carcinomas of the breast

M. Papotti, A. Sapino, L. Righi, S. Chiappone, G. Bussolati

Research output: Contribution to journalArticle

Abstract

Neuroendocrine (NE) carcinomas of the breast share morphologic and immunohistochemical features with NE tumors of other sites, either resembling typical carcinoids or the highly aggressive small cell carcinoma. In addition, some mucinous carcinomas or solid/papillary carcinomas may show a major NE component. This is generally recognized by specific immunodetection of pan-endocrine markers, although this approach may fail to recognize NE tumors lacking immunoreactivity for some NE products, because the antigen is produced but not retained in the cytoplasm. It has recently been reported that high molecular weight (HMW) cytokeratin (CK), recognized by clone 34βE12, immunostaining selectively labels non-NE carcinomas (squamous-cell and adenocarcinomas) of the aerodigestive tract and lung. The role of such CK immunodetection in the differential diagnosis of NE carcinoma of the breast was evaluated. Twenty-four cases of breast carcinomas having NE differentiation were selected. Twenty-four cases of non-NE invasive breast carcinomas served as controls. HMW CK immunoreactivity was found in all but one case of non-NE carcinomas, but in only two NE tumors (having scattered positive cells only). The authors conclude that in breast carcinomas the presence of HMW CK immunoreactivity favors the diagnosis of non-NE carcinoma, whereas its absence supports that of a NE tumor (either a carcinoid or a small cell carcinoma or a mucinous carcinoma). HMW CK can be added to the list of markers useful in the differential diagnosis of NE from non-NE tumors.

Original languageEnglish
Pages (from-to)229-233
Number of pages5
JournalApplied Immunohistochemistry and Molecular Morphology
Volume9
Issue number3
DOIs
Publication statusPublished - 2001

Fingerprint

Neuroendocrine Cells
Keratins
Adenocarcinoma
Breast
Differential Diagnosis
Epithelial Cells
Neuroendocrine Tumors
Molecular Weight
Carcinoid Tumor
Cytoplasm

Keywords

  • Breast
  • Clone 34βE12
  • High molecular weight cytokeratin
  • Immunohistochemistry
  • Neuroendocrine carcinoma

ASJC Scopus subject areas

  • Anatomy
  • Medical Laboratory Technology

Cite this

34βE12 cytokeratin immunodetection in the differential diagnosis of neuroendocrine carcinomas of the breast. / Papotti, M.; Sapino, A.; Righi, L.; Chiappone, S.; Bussolati, G.

In: Applied Immunohistochemistry and Molecular Morphology, Vol. 9, No. 3, 2001, p. 229-233.

Research output: Contribution to journalArticle

@article{8650fb675a644b5fa4fc568dd3ed69bf,
title = "34βE12 cytokeratin immunodetection in the differential diagnosis of neuroendocrine carcinomas of the breast",
abstract = "Neuroendocrine (NE) carcinomas of the breast share morphologic and immunohistochemical features with NE tumors of other sites, either resembling typical carcinoids or the highly aggressive small cell carcinoma. In addition, some mucinous carcinomas or solid/papillary carcinomas may show a major NE component. This is generally recognized by specific immunodetection of pan-endocrine markers, although this approach may fail to recognize NE tumors lacking immunoreactivity for some NE products, because the antigen is produced but not retained in the cytoplasm. It has recently been reported that high molecular weight (HMW) cytokeratin (CK), recognized by clone 34βE12, immunostaining selectively labels non-NE carcinomas (squamous-cell and adenocarcinomas) of the aerodigestive tract and lung. The role of such CK immunodetection in the differential diagnosis of NE carcinoma of the breast was evaluated. Twenty-four cases of breast carcinomas having NE differentiation were selected. Twenty-four cases of non-NE invasive breast carcinomas served as controls. HMW CK immunoreactivity was found in all but one case of non-NE carcinomas, but in only two NE tumors (having scattered positive cells only). The authors conclude that in breast carcinomas the presence of HMW CK immunoreactivity favors the diagnosis of non-NE carcinoma, whereas its absence supports that of a NE tumor (either a carcinoid or a small cell carcinoma or a mucinous carcinoma). HMW CK can be added to the list of markers useful in the differential diagnosis of NE from non-NE tumors.",
keywords = "Breast, Clone 34βE12, High molecular weight cytokeratin, Immunohistochemistry, Neuroendocrine carcinoma",
author = "M. Papotti and A. Sapino and L. Righi and S. Chiappone and G. Bussolati",
year = "2001",
doi = "10.1097/00022744-200109000-00006",
language = "English",
volume = "9",
pages = "229--233",
journal = "Applied Immunohistochemistry and Molecular Morphology",
issn = "1541-2016",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - 34βE12 cytokeratin immunodetection in the differential diagnosis of neuroendocrine carcinomas of the breast

AU - Papotti, M.

AU - Sapino, A.

AU - Righi, L.

AU - Chiappone, S.

AU - Bussolati, G.

PY - 2001

Y1 - 2001

N2 - Neuroendocrine (NE) carcinomas of the breast share morphologic and immunohistochemical features with NE tumors of other sites, either resembling typical carcinoids or the highly aggressive small cell carcinoma. In addition, some mucinous carcinomas or solid/papillary carcinomas may show a major NE component. This is generally recognized by specific immunodetection of pan-endocrine markers, although this approach may fail to recognize NE tumors lacking immunoreactivity for some NE products, because the antigen is produced but not retained in the cytoplasm. It has recently been reported that high molecular weight (HMW) cytokeratin (CK), recognized by clone 34βE12, immunostaining selectively labels non-NE carcinomas (squamous-cell and adenocarcinomas) of the aerodigestive tract and lung. The role of such CK immunodetection in the differential diagnosis of NE carcinoma of the breast was evaluated. Twenty-four cases of breast carcinomas having NE differentiation were selected. Twenty-four cases of non-NE invasive breast carcinomas served as controls. HMW CK immunoreactivity was found in all but one case of non-NE carcinomas, but in only two NE tumors (having scattered positive cells only). The authors conclude that in breast carcinomas the presence of HMW CK immunoreactivity favors the diagnosis of non-NE carcinoma, whereas its absence supports that of a NE tumor (either a carcinoid or a small cell carcinoma or a mucinous carcinoma). HMW CK can be added to the list of markers useful in the differential diagnosis of NE from non-NE tumors.

AB - Neuroendocrine (NE) carcinomas of the breast share morphologic and immunohistochemical features with NE tumors of other sites, either resembling typical carcinoids or the highly aggressive small cell carcinoma. In addition, some mucinous carcinomas or solid/papillary carcinomas may show a major NE component. This is generally recognized by specific immunodetection of pan-endocrine markers, although this approach may fail to recognize NE tumors lacking immunoreactivity for some NE products, because the antigen is produced but not retained in the cytoplasm. It has recently been reported that high molecular weight (HMW) cytokeratin (CK), recognized by clone 34βE12, immunostaining selectively labels non-NE carcinomas (squamous-cell and adenocarcinomas) of the aerodigestive tract and lung. The role of such CK immunodetection in the differential diagnosis of NE carcinoma of the breast was evaluated. Twenty-four cases of breast carcinomas having NE differentiation were selected. Twenty-four cases of non-NE invasive breast carcinomas served as controls. HMW CK immunoreactivity was found in all but one case of non-NE carcinomas, but in only two NE tumors (having scattered positive cells only). The authors conclude that in breast carcinomas the presence of HMW CK immunoreactivity favors the diagnosis of non-NE carcinoma, whereas its absence supports that of a NE tumor (either a carcinoid or a small cell carcinoma or a mucinous carcinoma). HMW CK can be added to the list of markers useful in the differential diagnosis of NE from non-NE tumors.

KW - Breast

KW - Clone 34βE12

KW - High molecular weight cytokeratin

KW - Immunohistochemistry

KW - Neuroendocrine carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0034741809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034741809&partnerID=8YFLogxK

U2 - 10.1097/00022744-200109000-00006

DO - 10.1097/00022744-200109000-00006

M3 - Article

C2 - 11556750

AN - SCOPUS:0034741809

VL - 9

SP - 229

EP - 233

JO - Applied Immunohistochemistry and Molecular Morphology

JF - Applied Immunohistochemistry and Molecular Morphology

SN - 1541-2016

IS - 3

ER -